Independent cancer second opinion for UK patients

For patients across England, Scotland, Wales and Northern Ireland. Kim Lockheimer, PhD, DFM reviews NHS Genomic Medicine Service results, Signatera ctDNA reports and private panels, then prepares questions and evidence your NHS or private consultant can act on.

What Kim reviews

Price and scheduling

Every engagement starts with the $250 Orientation Call, credited in full toward any service you choose afterward. The Clarity Report is USD $2,000 (about £1,600). Active Case Management: $4,500 / month; Concierge Advisory: $7,500 / month.

Video calls in GMT / BST. Paid receipts are suitable for Bupa, AXA Health, Vitality, and other private medical insurance reimbursement where policies allow.

Book an Orientation Call ($250)

All fees are in US dollars and payable online by card. Calls are scheduled to fit your time zone. Records in languages other than English may require translation before review.

Calls are with Kim Lockheimer, PhD, DFM, Chief Scientific Officer. Prices in local currency: /uk/pricing.

Advisory only: diagnosis and treatment stay with your treating oncologist.

Signatera test in the UK: access, cost and what results mean

Signatera is a personalized ctDNA blood test built from your own tumor's mutations. It is used to look for traces of cancer after surgery and to monitor over time. In the UK it is mostly available privately rather than routinely through the NHS, so patients often arrange it themselves or through a private consultant.

A positive result means tumor DNA was detected, which can come before anything shows on a scan. A negative result is reassuring but does not rule out recurrence, and the timing and frequency of testing matter. Kim reviews the report, explains what the numbers mean in context, and prepares questions for your NHS or private oncologist.

Guardant360 for UK patients

Guardant360 is a blood-based genomic test that looks for targetable mutations without a new biopsy. It can help when tissue is limited or a fresh biopsy is difficult, though it can miss changes when little tumor DNA is in the blood.

Kim checks whether a Guardant360 result fits with your NHS Genomic Medicine Service testing, whether anything actionable was found, and whether UK or EU trials match your profile.

Guides for patients

Other regions